Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
Identifieur interne : 001C32 ( Ncbi/Merge ); précédent : 001C31; suivant : 001C33Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
Auteurs : Soon Thye Lim [États-Unis] ; Anil Tupule ; Byron M. Espina ; Alexandra M. LevineSource :
- Cancer [ 0008-543X ] ; 2005.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de survie, Calendrier d'administration des médicaments, Femelle, Humains, Mâle, Perfusions veineuses, Relation dose-effet des médicaments, Résultat thérapeutique, Sarcome de Kaposi (), Sarcome de Kaposi (anatomopathologie), Sarcome de Kaposi (mortalité), Sarcome de Kaposi (traitement médicamenteux), Stade de la tumeur, Syndrome d'immunodéficience acquise (), Taxoïdes (administration et posologie), Taxoïdes (effets indésirables), Tumeurs cutanées (), Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (mortalité), Études de suivi, Évaluation des risques.
- MESH :
- administration et posologie : Taxoïdes.
- anatomopathologie : Sarcome de Kaposi, Tumeurs cutanées.
- effets indésirables : Taxoïdes.
- mortalité : Sarcome de Kaposi, Tumeurs cutanées.
- traitement médicamenteux : Sarcome de Kaposi.
- Adulte, Adulte d'âge moyen, Analyse de survie, Calendrier d'administration des médicaments, Femelle, Humains, Mâle, Perfusions veineuses, Relation dose-effet des médicaments, Résultat thérapeutique, Sarcome de Kaposi, Stade de la tumeur, Syndrome d'immunodéficience acquise, Tumeurs cutanées, Études de suivi, Évaluation des risques.
English descriptors
- KwdEn :
- Acquired Immunodeficiency Syndrome (complications), Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasm Staging, Risk Assessment, Sarcoma, Kaposi (complications), Sarcoma, Kaposi (drug therapy), Sarcoma, Kaposi (mortality), Sarcoma, Kaposi (pathology), Skin Neoplasms (complications), Skin Neoplasms (mortality), Skin Neoplasms (pathology), Survival Analysis, Taxoids (administration & dosage), Taxoids (adverse effects), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Taxoids.
- chemical , adverse effects : Taxoids.
- complications : Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Skin Neoplasms.
- drug therapy : Sarcoma, Kaposi.
- mortality : Sarcoma, Kaposi, Skin Neoplasms.
- pathology : Sarcoma, Kaposi, Skin Neoplasms.
- Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasm Staging, Risk Assessment, Survival Analysis, Treatment Outcome.
Abstract
Intravenous paclitaxel, 100 mg/m(2), given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). However, this regimen is associated with significant myelosuppression, and the inconvenience of a 3-hour infusion. Moreover, no effective therapies have been defined for use after treatment failure with this agent. A Phase II trial was conducted with weekly docetaxel in patients with advanced-stage KS to assess safety and antitumor activity.
DOI: 10.1002/cncr.20780
PubMed: 15578686
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003E38
- to stream PubMed, to step Curation: 003E38
- to stream PubMed, to step Checkpoint: 003E38
Links to Exploration step
pubmed:15578686Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.</title><author><name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon Thye" last="Lim">Soon Thye Lim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology, University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California 90033</wicri:regionArea><wicri:noRegion>California 90033</wicri:noRegion></affiliation></author><author><name sortKey="Tupule, Anil" sort="Tupule, Anil" uniqKey="Tupule A" first="Anil" last="Tupule">Anil Tupule</name></author><author><name sortKey="Espina, Byron M" sort="Espina, Byron M" uniqKey="Espina B" first="Byron M" last="Espina">Byron M. Espina</name></author><author><name sortKey="Levine, Alexandra M" sort="Levine, Alexandra M" uniqKey="Levine A" first="Alexandra M" last="Levine">Alexandra M. Levine</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15578686</idno><idno type="pmid">15578686</idno><idno type="doi">10.1002/cncr.20780</idno><idno type="wicri:Area/PubMed/Corpus">003E38</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003E38</idno><idno type="wicri:Area/PubMed/Curation">003E38</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003E38</idno><idno type="wicri:Area/PubMed/Checkpoint">003E38</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003E38</idno><idno type="wicri:Area/Ncbi/Merge">001C32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.</title><author><name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon Thye" last="Lim">Soon Thye Lim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology, University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California 90033</wicri:regionArea><wicri:noRegion>California 90033</wicri:noRegion></affiliation></author><author><name sortKey="Tupule, Anil" sort="Tupule, Anil" uniqKey="Tupule A" first="Anil" last="Tupule">Anil Tupule</name></author><author><name sortKey="Espina, Byron M" sort="Espina, Byron M" uniqKey="Espina B" first="Byron M" last="Espina">Byron M. Espina</name></author><author><name sortKey="Levine, Alexandra M" sort="Levine, Alexandra M" uniqKey="Levine A" first="Alexandra M" last="Levine">Alexandra M. Levine</name></author></analytic><series><title level="j">Cancer</title><idno type="ISSN">0008-543X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired Immunodeficiency Syndrome (complications)</term><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Risk Assessment</term><term>Sarcoma, Kaposi (complications)</term><term>Sarcoma, Kaposi (drug therapy)</term><term>Sarcoma, Kaposi (mortality)</term><term>Sarcoma, Kaposi (pathology)</term><term>Skin Neoplasms (complications)</term><term>Skin Neoplasms (mortality)</term><term>Skin Neoplasms (pathology)</term><term>Survival Analysis</term><term>Taxoids (administration & dosage)</term><term>Taxoids (adverse effects)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Perfusions veineuses</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Sarcome de Kaposi ()</term><term>Sarcome de Kaposi (anatomopathologie)</term><term>Sarcome de Kaposi (mortalité)</term><term>Sarcome de Kaposi (traitement médicamenteux)</term><term>Stade de la tumeur</term><term>Syndrome d'immunodéficience acquise ()</term><term>Taxoïdes (administration et posologie)</term><term>Taxoïdes (effets indésirables)</term><term>Tumeurs cutanées ()</term><term>Tumeurs cutanées (anatomopathologie)</term><term>Tumeurs cutanées (mortalité)</term><term>Études de suivi</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Taxoids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Taxoïdes</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Sarcome de Kaposi</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>Sarcoma, Kaposi</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Taxoïdes</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Sarcoma, Kaposi</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Sarcome de Kaposi</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Sarcoma, Kaposi</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sarcome de Kaposi</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Risk Assessment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Perfusions veineuses</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Sarcome de Kaposi</term><term>Stade de la tumeur</term><term>Syndrome d'immunodéficience acquise</term><term>Tumeurs cutanées</term><term>Études de suivi</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intravenous paclitaxel, 100 mg/m(2), given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). However, this regimen is associated with significant myelosuppression, and the inconvenience of a 3-hour infusion. Moreover, no effective therapies have been defined for use after treatment failure with this agent. A Phase II trial was conducted with weekly docetaxel in patients with advanced-stage KS to assess safety and antitumor activity.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15578686</PMID><DateCreated><Year>2005</Year><Month>01</Month><Day>17</Day></DateCreated><DateCompleted><Year>2005</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-543X</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.</ArticleTitle><Pagination><MedlinePgn>417-21</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Intravenous paclitaxel, 100 mg/m(2), given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). However, this regimen is associated with significant myelosuppression, and the inconvenience of a 3-hour infusion. Moreover, no effective therapies have been defined for use after treatment failure with this agent. A Phase II trial was conducted with weekly docetaxel in patients with advanced-stage KS to assess safety and antitumor activity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Docetaxel was administered at a dose of 25 mg/m(2) intravenously over 15-30 minutes weekly for 8 weeks. Thereafter, if the patient experienced stable disease or better response, treatment doses were given every other week until complete disease remission, disease progression, or unacceptable toxicity occurred.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve patients were accrued-9 had > 25 mucocutaneous lesions, 1 had lymphedema, and 2 had visceral involvement. Ten patients (83%) had previous systemic chemotherapy, including 4 who received previous paclitaxel. Treatment was well tolerated, with no Grade 4 toxicity of any type. Grade 3 neutropenia occurred in 33% of patients but no patient had neutropenic fever. Five patients (42%) achieved a partial response, including 1 who had previously failed to respond to paclitaxel. The median time to disease progression was 26 months (range, 5-53 months). With a median follow-up period of 45 months, the median survival point had not been reached.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Weekly docetaxel is safe, with reasonable antitumor activity in patients with advanced-stage, recurrent, or refractory AIDS-related KS.</AbstractText><CopyrightInformation>(c) 2004 American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Soon Thye</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tupule</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Espina</LastName><ForeName>Byron M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Alexandra M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>15H5577CQD</RegistryNumber><NameOfSubstance UI="C067311">docetaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="N">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15578686</ArticleId><ArticleId IdType="doi">10.1002/cncr.20780</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Espina, Byron M" sort="Espina, Byron M" uniqKey="Espina B" first="Byron M" last="Espina">Byron M. Espina</name><name sortKey="Levine, Alexandra M" sort="Levine, Alexandra M" uniqKey="Levine A" first="Alexandra M" last="Levine">Alexandra M. Levine</name><name sortKey="Tupule, Anil" sort="Tupule, Anil" uniqKey="Tupule A" first="Anil" last="Tupule">Anil Tupule</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon Thye" last="Lim">Soon Thye Lim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001C32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15578686
|texte= Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15578686" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |